RU58841 caused chest tightness, throat irritation, and headaches, leading the user to stop its use. The user plans to restart with a lower dose if symptoms fully disappear but remains cautious due to anxiety and side effects.
The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.
Oral minoxidil has shown positive results for hair regrowth, but concerns about its side effects, such as heart issues, are noted. Adding a DHT blocker like finasteride is recommended for better and more lasting results.
The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.
A 20-year-old saw significant hair regrowth after 9 months of using DHT blockers (finasteride and dutasteride) and 6 months of hormone replacement therapy (HRT) with estradiol. The regrowth is attributed to low testosterone and high estradiol levels, without using Minoxidil.
The conversation discusses hair loss treatments, specifically using dutasteride (0.5mg daily) with no side effects reported after two months. It also mentions the health benefits of one meal per day and the low incidence of side effects.
Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.
The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
Reducing DHT in the scalp is ideal for hair retention, with topical finasteride and dutasteride being common treatments. Some users report side effects like reduced libido, while others experiment with higher doses for regrowth.
The conversation is about determining which type of Saw Palmetto, either Chamaerops humilis or Serenoa repens, is effective for inhibiting the 5 alpha reductase enzyme related to hair loss. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.
The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.
Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.
Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.
Stopping antihistamines may resolve neurological side effects when using finasteride. Users experienced muscle aches, headaches, and lethargy when combining the two.
Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.
The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.
Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.
The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.
The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.
The conversation discusses skepticism about DHT blocker supplements for hair loss, with many users recommending proven treatments like finasteride and minoxidil instead. Some users shared personal experiences with alternative treatments like beta-sitosterol and saw palmetto, noting side effects and limited effectiveness.
Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.
The user is considering using 0.5 mg dutasteride once every 5 or 7 days due to side effects from finasteride and is also looking into topical liposomal dutasteride and pyrilutamide to stop hair loss. The goal is to stop hair loss, not regrow hair.
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
Switching from finasteride to dutasteride and oral minoxidil led to thicker hair and reduced hairline recession. Occasional flushing from minoxidil will be managed by lowering the dose.